A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells

Biomaterials

Volumn 35, Issue 2, 2014, Pages 779-791

  Lathuilière, Aurélien ^a   Cosson, Steffen ^a   Lutolf, Matthias P ^a   Schneider, Bernard L ^a   Aebischer, Patrick ^a  

^a EPFL   (Switzerland)

Author keywords

Allogeneic cells; Cell encapsulation; Drug delivery; Exvivo gene therapy; Hydrogel

Indexed keywords

ALLOGENEIC CELLS; ATTRACTIVE STRATEGIES; CELL ENCAPSULATIONS; ENCAPSULATION SYSTEMS; EX-VIVO; INFLAMMATORY RESPONSE; POLYPROPYLENE MEMBRANE; RECOMBINANT ANTIBODY;

ANTIBODIES; BIOMIMETICS; CYTOLOGY; DRUG DELIVERY; GENETIC ENGINEERING; HYDROGELS; MAMMALS; OPTIMIZATION; POLYETHYLENE GLYCOLS; POLYPROPYLENE OXIDES; POLYPROPYLENES; RECOMBINANT PROTEINS; TISSUE;

CELLS;

MACROGOL; POLYPROPYLENE; RECOMBINANT PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL ENCAPSULATION; CELL MACROENCAPSULATION; CELL SURVIVAL; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; HYDROGEL; LONG TERM SURVIVAL; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL;

ALLOGENEIC CELLS; CELL ENCAPSULATION; DRUG DELIVERY; EX VIVO GENE THERAPY; HYDROGEL;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CELL TRANSPLANTATION; CELLS, IMMOBILIZED; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; FEMALE; GENETIC ENGINEERING; HYDROGELS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED C57BL; MYOBLASTS; NEOVASCULARIZATION, PHYSIOLOGIC; QUALITY CONTROL; RECOMBINANT PROTEINS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84886753139     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.071     Document Type: Article

References (40)

1. Zhang K., Hopkins J.J., Heier J.S., Birch D.G., Halperin L.S., Albini T.A., et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A 2011, 108:6241-6245.
2. Eriksdotter-Jonhagen M., Linderoth B., Lind G., Aladellie L., Almkvist O., Andreasen N., et al. Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012, 33:18-28.
3. Aebischer P., Schluep M., Deglon N., Joseph J.M., Hirt L., Heyd B., et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996, 2:696-699.
4. Bachoud-Levi A.C., Deglon N., Nguyen J.P., Bloch J., Bourdet C., Winkel L., et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000, 11:1723-1729.
5. Schneider B.L., Schwenter F., Pralong W.F., Aebischer P. Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery. Mol Ther 2003, 7:506-514.
6. Tarantal A.F., Lee C.C., Itkin-Ansari P. Real-time bioluminescence imaging of macroencapsulated fibroblasts reveals allograft protection in rhesus monkeys (Macaca mulatta). Transplantation 2009, 88:38-41.
7. Ehrbar M., Rizzi S.C., Schoenmakers R.G., Miguel B.S., Hubbell J.A., Weber F.E., et al. Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions. Biomacromolecules 2007, 8:3000-3007.
8. Ehrbar M., Rizzi S.C., Hlushchuk R., Djonov V., Zisch A.H., Hubbell J.A., et al. Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials 2007, 28:3856-3866.
9. Rinsch C., Dupraz P., Schneider B.L., Deglon N., Maxwell P.H., Ratcliffe P.J., et al. Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. Kidney Int 2002, 62:1395-1401.
10. Kishima H., Poyot T., Bloch J., Dauguet J., Conde F., Dolle F., et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis 2004, 16:428-439.
11. Bott K., Upton Z., Schrobback K., Ehrbar M., Hubbell J.A., Lutolf M.P., et al. The effect of matrix characteristics on fibroblast proliferation in 3D gels. Biomaterials 2010, 31:8454-8464.
12. Gilbert P.M., Havenstrite K.L., Magnusson K.E., Sacco A., Leonardi N.A., Kraft P., et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010, 329:1078-1081.
13. Broadhead K.W., Biran R., Tresco P.A. Hollow fiber membrane diffusive permeability regulates encapsulated cell line biomass, proliferation, and small molecule release. Biomaterials 2002, 23:4689-4699.
14. Anderson J.M. Biological responses to materials. Annu Rev Mater Res 2001, 31:81-110.
15. Gerritsen M., Jansen J.A., Kros A., Vriezema D.M., Sommerdijk N.A., Nolte R.J., et al. Influence of inflammatory cells and serum on the performance of implantable glucose sensors. JBiomed Mater Res 2001, 54:69-75.
16. Sharkawy A., Klitzman B., Truskey G., Reichert W. Diffusion properties of tissue which encapsulates subcutaneous implants. Abstr Pap Am Chem Soc 1997, 213. 342-PMSE.
17. Ehrbar M., Sala A., Lienemann P., Ranga A., Mosiewicz K., Bittermann A., et al. Elucidating the role of matrix stiffness in 3D cell migration and remodeling. Biophys J 2011, 100:284-293.
18. Loessner D., Stok K.S., Lutolf M.P., Hutmacher D.W., Clements J.A., Rizzi S.C. Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31:8494-8506.
19. Lanza R.P., Langer R.S., Vacanti J. Principles of tissue engineering 2000, Academic Press, San Diego. 2nd ed.
20. Trautmann A. Extracellular ATP in the immune system: more than just a "danger signal". Sci Signal 2009, 2:pe6.
21. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
22. Colton C.K. Implantable biohybrid artificial organs. Cell Transplant 1995, 4:415-436.
23. De Vos P., Van Straaten J.F., Nieuwenhuizen A.G., de Groot M., Ploeg R.J., De Haan B.J., et al. Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth?. Diabetes 1999, 48:1381-1388.
24. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., Johnson R.S. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003, 23:359-369.
25. Di Carlo A., De Mori R., Martelli F., Pompilio G., Capogrossi M.C., Germani A. Hypoxia inhibits myogenic differentiation through accelerated MyoD degradation. JBiol Chem 2004, 279:16332-16338.
26. Yun Z., Lin Q., Giaccia A.J. Adaptive myogenesis under hypoxia. Mol Cell Biol 2005, 25:3040-3055.
27. Régulier E., Schneider B.L., Déglon N., Beuzard Y., Aebischer P. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther 1998, 5:1014-1022.
28. Schwenter F., Zarei S., Luy P., Padrun V., Bouche N., Lee J.S., et al. Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy. Cancer Gene Ther 2011, 18:553-562.
29. Gimble J.M., Katz A.J., Bunnell B.A. Adipose-derived stem cells for regenerative medicine. Circ Res 2007, 100:1249-1260.
30. Sensebe L., Bourin P., Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 2011, 22:19-26.
31. Tian H., Bharadwaj S., Liu Y., Ma H., Ma P.X., Atala A., et al. Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering. Biomaterials 2010, 31:870-877.
32. Gang E.J., Jeong J.A., Hong S.H., Hwang S.H., Kim S.W., Yang I.H., et al. Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. Stem Cells 2004, 22:617-624.
33. Meyerrose T.E., Roberts M., Ohlemiller K.K., Vogler C.A., Wirthlin L., Nolta J.A., et al. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells 2008, 26:1713-1722.
34. Eliopoulos N., Al-Khaldi A., Crosato M., Lachapelle K., Galipeau J. Aneovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged invivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 2003, 10:478-489.
35. Kucic T., Copland I.B., Cuerquis J., Coutu D.L., Chalifour L.E., Gagnon R.F., et al. Mesenchymal stromal cells genetically engineered to overexpress IGF-I enhance cell-based gene therapy of renal failure-induced anemia. Am J Physiol Renal Physiol 2008, 295:F488-F496.
36. Aslan H., Sheyn D., Gazit D. Genetically engineered mesenchymal stem cells: applications in spine therapy. Regen Med 2009, 4:99-108.
37. Balyasnikova I.V., Ferguson S.D., Sengupta S., Han Y., Lesniak M.S. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS ONE 2010, 5:e9750.
38. Razban V., Lotfi A.S., Soleimani M., Ahmadi H., Massumi M., Khajeh S., et al. HIF-1alpha overexpression induces angiogenesis in mesenchymal stem cells. BioRes Open Access 2012, 1:174-183.
39. Liu L., Gao J., Yuan Y., Chang Q., Liao Y., Lu F. Hypoxia preconditioned human adipose derived mesenchymal stem cells enhance angiogenic potential via secretion of increased VEGF and bFGF. Cell Biol Int 2013, 37:551-560.
40. Lathuilière A., Bohrmann B., Kopetzki E., Schweitzer C., Jacobson H., Moniatte M., et al. Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation. Biomaterials 2014, 35:792-802.